June 17, 2022 -- Artiva Biotherapeutics has officially opened its previously announced U.S. corporate headquarters and laboratory facility in San Diego.
The 52,000-sq-ft facility includes a multisuite, custom-built current good manufacturing practices (cGMP) cell production center that supports natural killer (NK) and CAR NK cell production for Artiva's pipeline development and clinical trial supply.
The new facility supplements Artiva's research and manufacturing at its partner GC Cell's state-of-the-art 300,000-sq-ft cell center that was completed in 2018. That facility constitutes research labs, process development labs, and a 50,000-sq-ft cGMP cell therapy manufacturing facility in the Republic of Korea.
The two sites will further Artiva's development of the next generation of off-the-shelf NK-cell therapies for the treatment of solid and hematological cancers, the firm said.
Artiva's San Diego NK-cell therapy research and GMP manufacturing facility. Image courtesy of Artiva Biotherapeutics.
Copyright © 2022 scienceboard.net